title: Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen (CTX) in postmenopausal women with osteopenia: six-month study.
abstract: Several studies have shown that alpha-ketoglutaric acid (AKG) increases serum levels of proline and has beneficial effects on skeletal development. We studied the effect of alpha-ketoglutaric (AKG) acid calcium salt (6 g AKG and 1.68 Ca/day) or calcium alone (1.68 Ca/day) on serum C-terminal cross-linked telopeptide of type I collagen (CTX) and osteocalcin (OC), as well as on lumbar spine bone mineral density (BMD) in a randomized, parallel group, double-blind, 6-month study conducted on 76 postmenopausal women with osteopenia. The maximum decrease of the mean CTX level in the AKG-Ca group was observed after 24 weeks (37.0%, p = 0.006). The differences in CTX between study groups were statistically significant after 12 and 24 weeks. The OC serum level was not affected by treatments. The BMD of the AKG-Ca group increased by 1.6% from baseline; however, the difference between treatment groups was estimated as 0.9% (non-significant). This study suggests the potential usefulness of AKG-Ca in osteopenic postmenopausal women. AKG-Ca induced beneficial changes in serum CTX, which was consistent with preserving the bone mass in the lumbar spine; however, the long-term effect needs to be further investigated.
authors: Department of Bone Metabolic Diseases, Institute of Agricultural Medicine, Jaczewskiego 2, 20-950 Lublin, Poland. r.s.filip@wp.pl
authors: Rafał S
authors: RS
authors: Filip
authors: Stefan G
authors: SG
authors: Pierzynowski
authors: Birger
authors: B
authors: Lindegard
authors: Jan
authors: J
authors: Wernerman
authors: Agnieszka
authors: A
authors: Haratym-Maj
authors: Małgorzata
authors: M
authors: Podgurniak
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000097:blood*; D024042:Collagen Type I / Q000097:blood* / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007656:Ketoglutaric Acids / Q000008:administration & dosage / Q000494:pharmacology*; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood / Q000187:drug effects; D010455:Peptides / Q000097:blood* / Q000187:drug effects; D017698:Postmenopause / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D007656:Ketoglutaric Acids; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin